AMO Pharma won regulator agreement from the FDA, U.K. MHRA and Health Canada to use hospitalization frequency as the primary endpoint in a placebo-controlled pivotal trial of AMO-02 for congenital myotonic dystrophy. The decision was shaped by patient input and aims to address the disease’s heterogenous presentation. The trial will include functional assessments as secondary measures, and AMO expects to announce trial-start details in Q3. This approach could influence endpoint selection in other ultra-rare disease programs.
FDA, MHRA and Health Canada Accept Hospitalization As Primary Endpoint In AMO Pharma’s Rare-Disease Trial
FDA allows unique endpoint in rare disease study
AMO Pharma last month secured a notable regulatory concession: the U.S. Food and Drug Administration, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada agreed that the rate of hospitalization can serve as the primary efficacy endpoint in the company’s pivotal registration trial of AMO-02 for congenital myotonic dystrophy.
Why Hospitalization?
Congenital myotonic dystrophy is an inherited neuromuscular disease with a small patient population and highly variable clinical presentations. It can affect mobility, heart and lung function, vision and swallowing, making it difficult to select a single, consistent outcome measure for trials. AMO CEO Mike Snape called hospitalization a "simple" and "elegant" endpoint that captures a meaningful, patient-centered benefit across the spectrum of disease.
'Keeping my child out of the hospital for 12 months would mean so much,' a parent told company leaders early in the program — feedback that helped shape the study design.
Trial Design and Regulatory Context
AMO’s planned pivotal trial will be a conventional, placebo-controlled study that uses hospitalization frequency as the primary endpoint and includes several functional assessments as secondary outcomes. Company spokespeople said they expect to provide an update on trial initiation in the third quarter.
The decision reflects growing regulatory flexibility when evaluating therapies for ultra-rare diseases, where small patient numbers and heterogeneity often make standard endpoints impractical. Regulators have previously adapted requirements in other rare-disease programs, though the paths have sometimes been bumpy.
Related Precedents
- Stealth BioTherapeutics: Secured accelerated FDA approval in Barth syndrome using data from very small studies; the approval required post-market commitments and applied to a narrower population than the sponsor sought.
- Regenxbio: Initially faced an FDA pushback over lack of a placebo-controlled arm for a Hunter syndrome gene therapy despite earlier protocol agreement; the agency later accepted the existing clinical data, illustrating occasional inconsistency and back-and-forth in rare-disease regulatory review.
Implications
If AMO’s approach proves successful, hospitalization could become an accepted primary endpoint in other ultra-rare disease trials where patient-centered, global measures are more meaningful than narrowly focused functional tests. The case underlines the value of early and sustained patient engagement to identify outcomes that matter most to families and caregivers.
Snape emphasized the importance of meaningful measures: 'We never wanted to show a statistically significant 3% change in the strength of your middle finger or something. We wanted to look at something meaningful.'
AMO Pharma, which has two other rare-disease candidates in clinical development, plans to provide study-start updates in Q3.
Help us improve.
